This filing is purely administrative — it confirms the CVR record date with no change to the CVR terms or probability of payout. The CVRs are non-transferable and unlisted, so there is no trading vehicle. Monitor briquilimab's clinical and regulatory progress for any update on Priority Review Voucher eligibility.
Price Chart
Executive Summary
Jasper Therapeutics filed an 8-K confirming the record date (July 16, 2026) for contingent value rights (CVRs) issued to common stockholders in connection with the Kira Pharmaceuticals acquisition. Each CVR entitles holders to a pro rata portion of a $30.0 million milestone payment if the FDA issues a Priority Review Voucher for briquilimab by December 31, 2028. The CVRs are non-transferable and not listed on any exchange, making them a speculative, long-dated contingent payout with no near-term trading value.
Key Facts
- Record date for CVRs was July 16, 2026, the closing date of the Kira acquisition.
- Each CVR entitles holder to a pro rata portion of $30.0 million if FDA issues a Priority Review Voucher for briquilimab by December 31, 2028.
- CVRs are non-transferable, not certificated, and not listed on any exchange.
- If the milestone is achieved but not monetized by the expiration date, CVRs continue until the milestone payment is paid in full.
Financial Impact
Up to $30.0 million aggregate milestone payment contingent on FDA Priority Review Voucher issuance for briquilimab by December 31, 2028.
Risk Factors
- CVR milestone may never be achieved (FDA may not issue a Priority Review Voucher for briquilimab by 2028).
- Even if achieved, monetization timing is uncertain and payment could be delayed beyond the expiration date.
- CVRs are non-transferable and unlisted — holders have no liquidity or ability to trade the contingent value.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-083563 |
| Document: 0001213900-26-083563-index-headers.html | 0001213900-26-083563 |
| Document: 0001213900-26-083563-index.html | 0001213900-26-083563 |
| Document: 0001213900-26-083563.txt | 0001213900-26-083563 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | SC TO-I/A | $0.5100 | awaiting T+5 | — | $0.5054 (−0.90%) |
Oct 20, 2026 6d ago | DEF 14A | $0.4999 | awaiting T+5 | — | $0.5054 (+1.10%) |
Oct 15, 2026 11d ago | 8-K | $0.5321 $0.4956 | ▼ −6.86% | ▼ −5.85% | $0.5054 (−5.02%) |
Oct 15, 2026 11d ago | Press Release | $0.5320 $0.4960 | ▲ +6.77% | ▲ +5.75% | $0.5054 (+5.00%) |
Oct 14, 2026 12d ago | S-3 | $0.5321 $0.4956 | ▲ +6.86% | ▲ +5.85% | $0.5054 (+5.02%) |
Oct 7, 2026 19d ago | 8-K | $0.5697 $0.5010 | ▼ −12.06% | ▼ −11.08% | $0.5054 (−11.29%) |
Oct 7, 2026 19d ago | SC TO-I | $0.5697 $0.5010 | ▼ −12.06% | ▼ −11.08% | $0.5054 (−11.29%) |
Sep 24, 2026 4w ago | 25-NSE | $0.6091 $0.5652 | ▲ +7.21% | ▲ +6.99% | $0.5054 (+17.03%) |
Aug 14, 2026 10w ago | Press Release | $0.7901 $0.7160 | ▼ −9.38% | ▼ −8.01% | $0.5054 (−36.03%) |
Jul 31, 2026 12w ago | 8-K | $0.6300 $0.7095 | ▲ +12.62% | ▲ +9.11% | $0.5054 (−19.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers